Neumora Therapeutics (NASDAQ:NMRA - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Needham & Company LLC in a report issued on Friday, Benzinga reports. They currently have a $23.00 price objective on the stock. Needham & Company LLC's price objective indicates a potential upside of 35.61% from the stock's previous close.
Several other equities analysts have also commented on the stock. HC Wainwright assumed coverage on shares of Neumora Therapeutics in a report on Tuesday, October 1st. They issued a "buy" rating and a $30.00 price objective on the stock. Mizuho assumed coverage on shares of Neumora Therapeutics in a report on Monday, July 8th. They issued an "outperform" rating and a $20.00 price objective on the stock. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a report on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $22.83.
View Our Latest Stock Analysis on Neumora Therapeutics
Neumora Therapeutics stock opened at $16.96 on Friday. The firm has a 50 day simple moving average of $12.62 and a 200-day simple moving average of $11.34. Neumora Therapeutics has a 1-year low of $8.33 and a 1-year high of $21.00. The stock has a market cap of $2.71 billion and a price-to-earnings ratio of -6.63.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). Equities analysts expect that Neumora Therapeutics will post -1.48 earnings per share for the current fiscal year.
In other Neumora Therapeutics news, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the sale, the insider now directly owns 322,966 shares in the company, valued at $4,847,719.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Robert A. Lenz sold 5,563 shares of the firm's stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now directly owns 322,966 shares in the company, valued at approximately $4,847,719.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Robert A. Lenz sold 30,788 shares of the firm's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the completion of the sale, the insider now owns 339,205 shares in the company, valued at $4,006,011.05. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 96,489 shares of company stock worth $1,151,258 in the last ninety days. 26.40% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD purchased a new position in shares of Neumora Therapeutics in the 1st quarter valued at $10,354,000. Callan Capital LLC grew its position in shares of Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company's stock valued at $6,500,000 after buying an additional 456,207 shares during the last quarter. Rhumbline Advisers grew its position in shares of Neumora Therapeutics by 488.3% in the 2nd quarter. Rhumbline Advisers now owns 103,258 shares of the company's stock valued at $1,015,000 after buying an additional 85,706 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Neumora Therapeutics by 79.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company's stock valued at $1,099,000 after buying an additional 49,527 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Neumora Therapeutics during the 2nd quarter worth $566,000. 47.65% of the stock is owned by hedge funds and other institutional investors.
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.